A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · Annals of Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pathology +17

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Jonathan A. Ledermann, F. Raja, Christina Fotopoulou et al. · Annals of Oncology · 2013 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +14

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye et al. · Journal of Clinical Oncology · 2010 · 404 citations

Medicine, Gynecology, Oncology +16

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

Yuji Takebayashi, Philippe Pourquier, Drazen B. Zimonjic et al. · Nature Medicine · 2001 · 348 citations

Life Sciences, Cell Biology, Molecular Biology +16